NKTR

Business Context and Reporting Period

Company: Nektar Therapeutics
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2004
Business Overview: Nektar is a drug delivery technology company focused on three main platforms: Advanced PEGylation Technology, Pulmonary Technology, and Supercritical Fluids Technology. The company generates revenue primarily through collaborative research agreements with pharmaceutical partners (notably Pfizer) and sales of PEGylation products. The company has not yet achieved profitability and relies on capital markets and partner funding to finance operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total revenue increased slightly by 1% to $25.8 million. Contract research revenue rose $3.1 million (driven by Pfizer activity and a $2 million termination fee from Aventis-Behring), while product sales declined $2.8 million due to rescheduling of PEG product sales and lower demand.
• Net Loss: Net loss more than doubled to $40.0 million from $19.9 million. This was primarily driven by a $9.3 million loss on debt extinguishment and a significant increase in interest expense ($16.0 million vs. $4.2 million) related to debt conversions and cash payments.
• Liquidity: Cash and short-term investments increased significantly to $467.4 million, up from $286.0 million at the end of 2003. This was fueled by a $196.2 million net proceeds from a common stock offering in March 2004.
• Debt Reduction: Convertible subordinated notes decreased from $360.0 million (Dec 31, 2003) to $181.7 million (Mar 31, 2004) following the conversion of $133.3 million of 3% notes and other debt exchanges.

Guidance, Outlook, and Risks

• Capital Resources: Management forecasts sufficient cash to meet net operating expense requirements for at least the next two years. However, the company expects to continue incurring substantial losses as it expands R&D and manufacturing.
• Debt Obligations: The company has significant debt maturities in 2006 ($7.8 million) and 2007 ($173.9 million). Management states it is unlikely to satisfy these obligations through operating cash flow alone and may need to raise additional capital or restructure debt.
• Key Dependencies:
  • Pfizer Collaboration: Pfizer represents 59% of revenue. The company's financial position is heavily dependent on the regulatory approval and commercial launch of Exubera (inhaled insulin) by Pfizer and Aventis.
  • Regulatory Approval: Exubera has been filed for marketing authorization in Europe (EMEA), but U.S. FDA approval timing remains uncertain. Delays or failure to approve Exubera would materially harm the company.
• Accounting Restatement: In April 2004, the company restated its 2003 financials to reduce a previously recorded gain on debt extinguishment by $19.2 million, increasing the 2003 net loss. This was due to a change in accounting principle (EITF 96-19).
• Risk Factors: Risks include failure of collaborative partners to commercialize products, inability to scale manufacturing, patent litigation, and the need for future equity/debt financing which may result in dilution.

Investor Verification Checklist

• Debt Maturity Profile: Verify the company's plan to refinance or repay the $173.9 million in debt maturing in 2007, given the lack of current operating cash flow.
• Exubera Timeline: Monitor Pfizer/Aventis announcements regarding the EMEA marketing authorization and the timing of the U.S. NDA filing, as this drives the majority of revenue.
• Restatement Impact: Review the full details of the April 2004 restatement regarding the 2003 debt exchange to understand the full impact on historical comparability.
• Customer Concentration: Assess the risk of revenue volatility given that Pfizer accounted for 59% of revenue in Q1 2004.
• Capital Expenditures: Track the expansion of the Alabama manufacturing facility and its impact on cash burn rates.